Clinical trial
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Macroglobulinemia of Waldenstrom
NCT00003512 is registered in ClinicalTrials.gov with Burzynski Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Macroglobulinemia of Waldenstrom
- Lead sponsor
- Burzynski Research Institute
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- February 18, 1999
- Completion date
- April 26, 2000
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.